Nature Communications publishes a steady stream of peptide-relevant primary research — typically mechanism work, structural biology, and AI-driven discovery papers that don't fit the broader Nature flagship. The journal is a regular source on this site for de novo peptide design, antimicrobial peptide work, peptide-drug conjugate chemistry, and structural studies on intracellular protein–protein interaction targets.
Representative pieces covered here: AI-discovered antimicrobial scaffolds, structural work on macrocyclic peptide binding to undruggable targets, bicyclic peptide chemistry from Bicycle Therapeutics and academic collaborators, and HLB Innovation's HMD-AMP transformer-based AMP discovery work.
Use this tag to scan the Nature Communications coverage. For broader Nature family work, see #nature-medicine for clinical and translational pieces.
A Nature Communications paper (2026) introduces CycloPepper, a machine-learning-guided platform for predicting cyclization outcomes and accelerating automated synthesis of therapeutic cyclic peptides. The model addresses one of the persistent bottlenecks in cyclic-peptide drug development: many promising linear sequences fail at the macrocyclization step or yield poorly under standard conditions, requiring expensive iterative chemistry. CycloPepper trains on a curated dataset of cyclization outcomes and integrates with automated synthesis platforms to enable closed-loop design-make-test cycles. The work joins CyclicMPNN (a fine-tuned ProteinMPNN derivative for cyclic peptide sequence design) and AfCycDesign as part of a fast-maturing computational stack for cyclic-peptide therapeutics.
A Nature Communications umbrella review by Kong, Zhao, Zhang and colleagues synthesized 123 meta-analyses covering 464 outcomes from 5,617 articles to comprehensively assess GLP-1 receptor agonist effectiveness and adverse events across diverse outcomes. Outcomes were grouped into seven categories: endocrine and metabolic, cardiovascular, cancer, renal, respiratory, mortality and adverse events, and other. The review documented improvements in metabolic, cardiovascular, renal, and respiratory outcomes plus cognitive function, with potential reductions in fracture risk and all-cause mortality in selected populations. Increased risks were observed for diabetic retinopathy, ketoacidosis, gastrointestinal events, and treatment discontinuation — useful evidence-summary input for ECO 2026 in Istanbul (May 12–15) and the prevention-trial proposal that 21 obesity-and-cancer experts will present there.
Saha, Xu, Panda, and Micklefield at the University of Manchester and Manchester Institute of Biotechnology published a Nature Communications paper April 30 describing a fundamentally simpler biosynthetic route to penicillin antibiotics. Instead of the traditional ACV tripeptide assembled by complex non-ribosomal peptide synthetase (NRPS) machinery, the team uses standalone glutathione-style ligase and epimerase enzymes to generate the peptide precursor, then transforms it with an engineered isopenicillin N synthase (IPNS) to produce penicillin G, penicillin V, and ampicillin directly. The pathway sidesteps the semisynthesis steps currently required for these penicillins and could simplify production at scale — material in an AMR landscape where supply economics matter as much as new chemistry.
A Nature Communications paper describes a deep-learning pipeline that uses pre-trained protein language models combined with few-shot fine-tuning to identify antimicrobial peptides effective against Acinetobacter baumannii, a WHO critical-priority pathogen. The classification, ranking, and regression modules collaboratively prioritize candidates with high predicted activity, expanding the chemical space accessible to data-poor AMR targets. Lead candidates showed potent in vitro activity against carbapenem-resistant clinical isolates.
A Nature Communications paper published April 27 mined natural diversity in Viola plants to discover 29 new peptide asparaginyl ligases (PALs) — enzymes that catalyze cyclization of synthetic peptide chains. The work characterizes a pH-dependent cyclization mechanism and defines transferable expression-increasing principles, substantially expanding the enzymatic toolkit available for cyclic peptide drug development. The discovery is timely given the surge of macrocyclic peptide programs at Circle Pharma, Bicycle Therapeutics, and Unnatural Products.
A Nature Communications paper published April 27 introduced DDA-BERT, an end-to-end transformer-based deep learning model for peptide identification in data-dependent acquisition (DDA) proteomics. The model improves peptide identification accuracy across multiple species and outperforms existing methods on HLA immunopeptidomics — directly relevant to neoantigen peptide vaccine discovery for personalized cancer immunotherapy. The work joins the broader 2026 wave of AI-driven peptide tooling captured in this month's ACS Biochemistry and Nature Biotechnology papers.
A Nature Communications paper introduced genetically encoded CRAC (calcium release-activated calcium) channel inhibitory binders — designated CRABs — derived from the ORAI C-terminal tail. Membrane-anchored CRAB variants potently inhibit Ca²⁺ influx and downstream NFAT signaling, offering a peptide-based modulator class for channelopathies, autoimmune disorders, and cancer immunotherapy applications. The mechanism complements existing CRAC channel small-molecule inhibitors and expands the toolkit for precision modulation of calcium signaling.
A Nature Communications paper introduced a broad-spectrum macrocyclic peptide inhibitor designed for intranasal administration that protects against multiple SARS-CoV-2 Omicron variants in preclinical models. The work expands the macrocyclic peptide modality beyond oncology into respiratory antivirals, where peptide stability and tissue penetration challenges have historically limited clinical translation. Published as Nature Communications article s41467-026-68462-9.
A Nature Communications paper introduced CycloSEL (Cyclic Self-Encoded Libraries), an end-to-end workflow that screens synthetic macrocycle libraries enriched in drug-like 'beyond rule of five' features using affinity selections and tandem mass spectrometry — eliminating the genetic-barcode requirement of traditional macrocyclic peptide discovery. The team validated the approach against the oncology target carbonic anhydrase IX with a 16-million-member library, achieving robust enrichment and accurate identification of true binders. The platform shifts peptide drug discovery toward small molecule-like drug-likeness optimization from day one.
A Nature Communications paper introduces CAMPER (Constraint-driven AMP Engineering with Ranking), a mechanistic AI framework that integrates machine learning with biophysical ranking to design membrane-targeting peptides against MRSA persisters and biofilms. The framework identified WP-CAMPER1, a 12-mer peptide that kills S. aureus MW2 at an MIC of 4 µg/mL; a 2% topical formulation reduced S. aureus burden by 2.5 log10 in a murine skin infection model.
A Nature Communications paper describes peptide dendron nanoassemblies that shape-shift in response to bacterial enzymes to eradicate intracellular drug-resistant bacteria while protecting host macrophages. The nanoassemblies combine self-assembling regions, cell-penetrating motifs, enzyme-responsive sequences, and integrin-targeting ligands, transforming from nanoparticles to nanofibers for prolonged cell retention before converting back to nanoparticles for cellular uptake.
A Nature Communications paper published April 15 reveals shared structural mechanisms between SbmA — an E. coli membrane transporter that imports antimicrobial peptides — and ABC transporters. Using cryo-electron microscopy, EPR spectroscopy, and molecular dynamics simulations, researchers demonstrated SbmA undergoes ABC-transporter-like conformational changes, informing strategies to design antibiotic-resistant-bacteria-penetrating peptide drugs.